Kubota Pharmaceutical Holdings Co., Ltd. (4596.T)

JPY 57.0

(0.0%)

Market Cap (In JPY)

3.21 Billion

Revenue (In JPY)

39.88 Million

Net Income (In JPY)

-1.48 Billion

Avg. Volume

463.75 Thousand

Currency
JPY
Country
Healthcare
Open
-
Prev. Close
-
Day Range
-
Year Range
50.0-104.0
PE
-
EPS
-
Beta Value
1.017
ISIN
JP3266500002
CUSIP
-
CIK
-
Shares
-
Earnings Annoncement
-

Company Profile

Sector
Healthcare
Industry
Biotechnology
CEO
Dr. Ryo Kubota M.D., Ph.D.
Employee Count
-
Website
https://www.kubotaholdings.co.jp
Ipo Date
2016-12-06
Details
Kubota Pharmaceutical Holdings Co., Ltd. develops portfolio of drugs and devices worldwide. Its product pipeline comprises emixustat hydrochloride, which is in Phase III clinical stage used for the treatment of stargardt disease, and Phase II clinical stage used for the treatment of proliferative diabetic retinopathy. The company is also developing remote retinal monitoring device patient-based ophthalmology suite, that includes home-based miniature and NASA high-res version optical coherence tomography devices; and wearable device for myopia control. The company was founded in 2002 and is based in Tokyo, Japan.